Objective
The primary objective of this study is to determine whether Roxadustat, a drug that stabilizes a protein called HIF-1 (Hypoxia-Inducible Factor-1), can improve kidney oxygenation in individuals with type 1 diabetes (T1D) and diabetic nephropathy (DN). The study will compare Roxadustat’s effectiveness to Darbepoetin alfa, a standard treatment for anemia in chronic kidney disease (CKD), to see if Roxadustat offers additional benefits for kidney health. The goal is to find a new treatment that can slow or prevent kidney damage in people with T1D, addressing a critical unmet need in their care.
To measure kidney oxygenation, the study will use a non-invasive imaging technique called Blood Oxygen-Level Dependent MRI (BOLD-MRI). This method allows researchers to assess oxygen levels in the kidneys without invasive procedures, providing valuable insights into how well the kidneys are functioning. The primary focus is to see if Roxadustat can improve kidney oxygenation more effectively than Darbepoetin alfa over a 24-week treatment period. If successful, this could mean that Roxadustat not only treats anemia but also protects the kidneys by addressing the underlying issue of hypoxia (low oxygen levels), which is a key driver of kidney damage in diabetes.
In addition to the primary objective, the study has several secondary objectives to evaluate the broader impact of Roxadustat on kidney health and overall well-being. These include measuring changes in kidney function (using urine albumin-to-creatinine ratio and estimated glomerular filtration rate), blood sugar control (using HbA1c, time in range, and glucose variability), and cardiovascular health (using levels of NT-proBNP, a biomarker for heart health). The study will also assess diabetes-related emotional distress using a validated questionnaire, providing insights into how the treatment affects patients’ quality of life.
Another important objective is to explore the safety and feasibility of using Roxadustat in T1D patients with kidney damage. While Roxadustat is already approved for treating anemia in CKD patients, its use in T1D patients with diabetic nephropathy is less studied. The study will carefully monitor participants for potential side effects, such as hypoglycemia (low blood sugar), to ensure that Roxadustat is safe for this specific patient population. This information will be crucial for guiding future clinical use and regulatory decisions.
If the study shows that Roxadustat improves kidney oxygenation and function, it could lead to larger clinical trials focusing on long-term kidney protection. These future studies might explore whether Roxadustat can reduce the risk of kidney failure, cardiovascular events, and other complications associated with diabetes. The findings could also have broader implications for other diabetes-related conditions, such as neuropathy (nerve damage) and ischemic heart disease, where HIF-1 activation may play a protective role.
In summary, the main objective of this study is to determine whether Roxadustat can improve kidney oxygenation and function in T1D patients with diabetic nephropathy, offering a new way to protect their kidneys and improve their quality of life. By comparing Roxadustat to Darbepoetin alfa and using advanced imaging techniques like BOLD-MRI, the study aims to provide valuable insights into the role of kidney hypoxia in diabetes and how HIF-1 activation can counteract this process. If successful, this research could lead to new treatments that address the root causes of kidney damage in T1D, offering hope for better long-term outcomes.
Background Rationale
Diabetes is a global health challenge, and one of its most serious complications is diabetic nephropathy (DN), where high blood sugar damages the kidneys over time. This is especially concerning for people with type 1 diabetes (T1D), who have fewer treatment options compared to those with type 2 diabetes. While therapies like GLP-1 receptor agonists and SGLT2 inhibitors help type 2 diabetes patients, similar breakthroughs for T1D-related kidney disease are lacking. This leaves a gap in care for T1D patients, who often rely on managing blood sugar and blood pressure to slow kidney damage. New treatments targeting the root causes of kidney damage in T1D are urgently needed.
A key factor in diabetic nephropathy is kidney hypoxia, where the kidneys don’t get enough oxygen. Research shows that in diabetes, the kidneys are often chronically hypoxic, which contributes to kidney damage and eventual failure. This hypoxia can appear early in diabetes, sometimes just days after diabetes begins in experimental models. Addressing kidney hypoxia could be a promising way to prevent or slow diabetic nephropathy.
The body’s ability to adapt to low oxygen is controlled by a protein called HIF-1 (Hypoxia-Inducible Factor-1). HIF-1 helps cells survive low oxygen by activating genes that promote blood vessel growth, improve energy use, and reduce cell death. However, in diabetes, this response is impaired. Even though the kidneys are hypoxic, HIF-1 doesn’t work properly, contributing to kidney damage. High blood sugar suppresses HIF-1 activity, and studies show that restoring HIF-1 function can reduce kidney damage in animal models. This suggests that targeting HIF-1 could be a viable treatment for diabetic nephropathy.
Recently, a new class of drugs called HIF-prolyl hydroxylase inhibitors (HIF-PHIs) has been developed to stabilize HIF-1alpha. One such drug, Roxadustat, is approved for treating anemia in chronic kidney disease (CKD) patients. Roxadustat has shown promise in improving kidney oxygenation and reducing kidney damage in preclinical studies. Unlike traditional treatments like Darbepoetin alfa, which mainly stimulate red blood cell production, Roxadustat’s ability to stabilize HIF-1 may offer additional benefits, such as reducing oxidative stress and improving kidney function, making it a potentially better treatment for diabetic nephropathy.
This study aims to explore whether Roxadustat can improve kidney oxygenation in T1D patients with diabetic nephropathy. It will use a non-invasive imaging technique called Blood Oxygen-Level Dependent MRI (BOLD-MRI) to measure changes in kidney oxygenation over 24 weeks. BOLD-MRI is a safe and effective way to assess kidney health, providing detailed information about oxygen levels in kidney tissue. The study will also evaluate kidney function, blood sugar control, and markers of cardiovascular health. Additionally, it will assess Roxadustat’s impact on diabetes-related emotional distress, an important aspect of quality of life for people with diabetes.
The rationale for this study is the urgent need for new treatments for diabetic nephropathy, especially in T1D patients. By targeting the HIF-1 pathway, Roxadustat offers a novel approach that could complement existing therapies and potentially slow kidney damage progression. If successful, this study could lead to larger clinical trials focusing on long-term kidney protection and improved outcomes for people with diabetes. The findings could also have broader implications for other diabetes-related complications, such as neuropathy and heart disease, where HIF-1 activation may play a protective role.
In summary, this study represents an important step forward in finding effective treatments for diabetic nephropathy. By focusing on kidney hypoxia and the HIF-1 pathway, it offers a promising new direction for improving the lives of people with T1D and reducing the burden of kidney disease.
Description of Project
Diabetic nephropathy (DN), or kidney disease caused by diabetes, is a major health challenge, particularly for people with type 1 diabetes (T1D). While there have been significant advances in treating DN in type 2 diabetes (T2D), individuals with T1D have limited treatment options beyond blood sugar control, blood pressure management, and cholesterol reduction. The FOXTROT study aims to address this gap by exploring a novel treatment approach targeting kidney oxygen levels.
Why This Study Matters
The kidneys rely on oxygen to function properly, but diabetes can cause a condition called kidney hypoxia, where oxygen levels drop too low. Research suggests that hypoxia plays a central role in the development of DN, leading to kidney failure over time. The FOXTROT study will investigate whether improving oxygen regulation in the kidneys can slow or prevent DN progression in T1D patients.
A key player in oxygen regulation is Hypoxia-Inducible Factor-1 (HIF-1), a protein that helps cells adapt to low oxygen levels. However, in diabetes, high blood sugar interferes with HIF-1’s function, making it harder for the kidneys to cope with hypoxia. Scientists believe that restoring HIF-1 activity could help protect the kidneys from damage.
The FOXTROT Study: Testing a New Approach
This study will evaluate the effects of Roxadustat, a medication that activates HIF-1, and compare it with Darbepoetin alpha, a standard treatment for anemia in chronic kidney disease. Roxadustat is already approved for treating kidney-related anemia in non-dialysis patients, and its safety is well-established. Researchers will examine whether Roxadustat provides additional benefits beyond treating anemia, specifically by improving kidney oxygen levels and slowing DN progression.
How the Study Works
The FOXTROT study is designed as a proof-of-concept trial, meaning it will test whether this new approach is feasible and effective before conducting larger studies. Participants with T1D and chronic kidney disease will be randomly assigned to receive either Roxadustat or Darbepoetin alpha for 24 weeks. The main goal is to measure changes in kidney oxygenation using a non-invasive imaging technique called Blood Oxygen Level-Dependent MRI (BOLD-MRI).
Additional Health Measures
Along with kidney oxygen levels, researchers will also monitor:
• Kidney function markers (urinary albumin-to-creatinine ratio [UACR] and estimated glomerular filtration rate [eGFR])
• Blood sugar control (HbA1c, insulin use, glucose variability)
• Heart health (NT-proBNP, a biomarker for cardiovascular risk)
• Circulating endothelial progenitor cells, which help repair blood vessels
• Oxidative stress markers (reactive oxygen species levels)
• Diabetes-related emotional distress, to assess quality of life
Potential Impact
If Roxadustat proves effective in improving kidney oxygenation, it could open the door to new treatments for DN that go beyond standard glucose control. This approach may also be relevant for other diabetes complications, such as heart disease and nerve damage, where oxygen regulation plays a role. Additionally, the study could lead to larger trials testing Roxadustat in T1D patients without anemia, focusing on long-term kidney protection.
By targeting kidney hypoxia, the FOXTROT study has the potential to revolutionize DN treatment for people with T1D, providing a much-needed therapeutic option that addresses a key disease mechanism.
Anticipated Outcome
This study aims to determine whether Roxadustat, a drug that stabilizes a protein called HIF-1 (Hypoxia-Inducible Factor-1), can improve kidney oxygenation in individuals with type 1 diabetes (T1D) and diabetic nephropathy (DN). The primary goal is to compare Roxadustat’s effectiveness to the standard treatment, Darbepoetin alfa, using a non-invasive imaging technique called Blood Oxygen-Level Dependent MRI (BOLD-MRI). If successful, this study could lead to new treatments that slow or prevent kidney damage in people with T1D, offering hope for better long-term outcomes.
The anticipated outcome is that Roxadustat will improve kidney oxygenation more effectively than Darbepoetin alfa. Roxadustat’s ability to stabilize HIF-1 not only increases red blood cell production (like Darbepoetin alfa) but also activates other protective mechanisms in the kidneys. These include reducing oxidative stress, improving energy metabolism, and promoting blood vessel growth, which could alleviate kidney hypoxia and slow the progression of diabetic nephropathy. By improving kidney oxygenation, Roxadustat may help preserve kidney function and delay the need for dialysis or transplantation in T1D patients.
In addition to measuring kidney oxygenation, the study will evaluate secondary outcomes, including kidney function (measured by urine albumin-to-creatinine ratio and estimated glomerular filtration rate), blood sugar control (measured by HbA1c, time in range, and glucose variability), and cardiovascular health (measured by NT-proBNP levels). The study will also assess diabetes-related emotional distress using a validated questionnaire, providing insights into how the treatment affects patients’ quality of life.
If Roxadustat shows positive results, it could lead to larger clinical trials focusing on long-term kidney protection. These future studies might explore whether Roxadustat can reduce the risk of kidney failure, cardiovascular events, and other diabetes-related complications, where HIF-1 activation may play a protective role, potentially improving outcomes for millions of people with diabetes.
Another anticipated outcome is a better understanding of kidney hypoxia in diabetic nephropathy. By using BOLD-MRI to measure changes in kidney oxygenation, researchers hope to clarify how hypoxia contributes to kidney damage and how stabilizing HIF-1 can counteract this process. This could lead to new biomarkers for early detection of kidney damage and more personalized treatment strategies.
The study also aims to demonstrate the safety and feasibility of using Roxadustat in T1D patients with kidney damage. While Roxadustat is approved for treating anemia in chronic kidney disease (CKD) patients, its use in T1D patients with kidney damage is less studied. By monitoring participants for side effects, such as hypoglycemia, the study will provide important safety data, guiding future clinical use and regulatory decisions.
If Roxadustat proves safe and effective, it could lead to changes in clinical practice. Currently, treatment options for diabetic nephropathy in T1D patients are limited, and there is a significant unmet need for therapies that target the underlying causes of kidney damage. Roxadustat, with its unique mechanism of action, could become a valuable addition to the treatment options for diabetic nephropathy, offering a new way to protect kidney function and improve outcomes for T1D patients.
Relevance to T1D
Diabetes is a chronic condition that affects millions of people worldwide, and type 1 diabetes (T1D) is a particularly challenging form of the disease. Unlike type 2 diabetes, which can often be managed with lifestyle changes and a variety of medications, T1D requires lifelong insulin therapy and careful monitoring of blood sugar levels. One of the most serious complications of T1D is diabetic nephropathy (DN), a condition where high blood sugar levels damage the kidneys over time. This can lead to kidney failure, requiring dialysis or a kidney transplant, and significantly impacts the quality of life for those affected.
Currently, treatment options for diabetic nephropathy in T1D patients are limited. While there have been significant advancements in therapies for type 2 diabetes, such as GLP-1 receptor agonists and SGLT2 inhibitors, these treatments are not as effective or widely used in T1D. As a result, T1D patients often rely on managing blood sugar levels, blood pressure, and cholesterol to slow the progression of kidney damage. However, these measures are not always sufficient, and there is a critical need for new treatments that directly target the underlying causes of kidney damage in T1D.
This study focuses on Roxadustat, a drug that stabilizes a protein called HIF-1 (Hypoxia-Inducible Factor-1), which plays a key role in how cells respond to low oxygen levels. In diabetes, the kidneys often become hypoxic, meaning they don’t receive enough oxygen, and this hypoxia contributes to kidney damage. HIF-1 is normally responsible for helping cells adapt to low oxygen conditions, but in diabetes, its function is impaired. Roxadustat works by stabilizing HIF-1, allowing it to function properly and potentially reducing kidney damage.
The relevance of this study to T1D is significant. By targeting the HIF-1 pathway, Roxadustat offers a novel approach to treating diabetic nephropathy that goes beyond simply managing blood sugar levels. If successful, this treatment could help preserve kidney function in T1D patients, delaying or even preventing the need for dialysis or a kidney transplant. This would be a major breakthrough for T1D patients, who currently have few options for protecting their kidneys.
Moreover, the study uses a non-invasive imaging technique called Blood Oxygen-Level Dependent MRI (BOLD-MRI) to measure changes in kidney oxygenation. This method provides detailed information about kidney health without the need for invasive procedures, making it easier and safer for patients to participate in the study. The use of BOLD-MRI also allows researchers to better understand how kidney hypoxia contributes to diabetic nephropathy, which could lead to new biomarkers for early detection and more personalized treatment strategies.
In addition to its potential benefits for kidney health, Roxadustat may also have broader implications for other complications of T1D. HIF-1 activation has been shown to play a protective role in conditions such as neuropathy (nerve damage) and ischemic heart disease, which are common in people with diabetes. If Roxadustat proves effective in improving kidney oxygenation, it could open the door to exploring its use in treating these and other diabetes-related complications.